Skip to content
MedsAcross

Fixed-dose combination

Atoltivimab, Maftivimab and Odesivimab

Also known as atoltivimab, maftivimab, odesivimab
Available on requestBiologicOrphanCold chain
Presentations
2
Brands
1
Manufacturers
1
Available from stock
0

Atoltivimab, Maftivimab and Odesivimab is a fixed-dose combination medicine indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother, among other approved uses. MedsAcross supplies Atoltivimab, Maftivimab and Odesivimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

US FDA first approval
14 October 2020
EU status
Not recorded
Orphan designation
Yes
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intravenous
Dosage forms
Injection
Biologic
Yes
Fixed-dose combination of
Atoltivimab, Maftivimab, Odesivimab

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. Limitation of Use The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.

Source: US FDA prescribing information

How it works

INMAZEB is an antiviral drug combination of three recombinant human IgG1κ monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Orthoebolavirus zairense.

Source: US FDA prescribing information

Dosing overview

The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion. Refer to the Full Prescribing Information for information on preparation and administration.

Source: US FDA prescribing information

Warnings and precautions

Hypersensitivity Reactions Including Infusion-Associated Events: Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor patients and in the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care.

Source: US FDA prescribing information

Side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Infusion-Associated Events The most common adverse events (incidence ≥20%) were pyrexia, chills, tachycardia, tachypnea, and vomiting.

Source: US FDA prescribing information

Interactions

Interaction with live vaccine indicated for prevention of Orthoebolavirus zairense infection: No vaccine interaction studies have been performed. INMAZEB may reduce the efficacy of the live vaccine. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines.

Source: US FDA prescribing information

Storage

Store INMAZEB vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake. Lactated Ringer's Injection, USP Store at room temperature up to 25°C (77°F) for no more than 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 4 hours. Store the diluted INMAZEB solution as specified according to Table 12 below. Do not freeze the diluted solution.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Atoltivimab, Maftivimab and Odesivimab, sorted by availability.

MedicineActive ingredientManufacturerRegisterAvailability
Inmazeb 241.7 mg/241.7 mg/241.7 mg per 14.5 mL injectionIntravenous Cold chainAtoltivimab, Maftivimab and OdesivimabRegeneron PharmaceuticalsUS FDAAvailable on request
Inmazeb 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injectionIntravenous Cold chainAtoltivimab, Maftivimab and OdesivimabRegeneron PharmaceuticalsUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Inmazeb

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 14 October 2020Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Atoltivimab, Maftivimab and Odesivimab available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Atoltivimab, Maftivimab and Odesivimab and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Atoltivimab, Maftivimab and Odesivimab have?

The catalogue lists 1 brand names for Atoltivimab, Maftivimab and Odesivimab, including Inmazeb.

Is Atoltivimab, Maftivimab and Odesivimab approved by the US FDA?

Yes. The US FDA first approved Atoltivimab, Maftivimab and Odesivimab on 14 October 2020, according to Drugs@FDA.

Does Atoltivimab, Maftivimab and Odesivimab need cold chain shipping?

At least one listed presentation of Atoltivimab, Maftivimab and Odesivimab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.

References

  1. Inmazeb prescribing information (Regeneron Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 15 December 2025

Request Atoltivimab, Maftivimab and Odesivimab for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quoteRead the import guides